title: Sex differences in Parkinson's disease and other movement disorders.
abstract: Movement disorders including Parkinson's disease (PD), Huntington's disease (HD), chorea, tics, and Tourette's syndrome (TS) display sex differences in disease susceptibility, disease pathogenesis, and clinical presentation. PD is more common in males than in females. Epidemiologic studies suggest that exposure to endogenous and exogenous estrogen contributes to these sex differences. There is extensive evidence that estrogen prevents dopaminergic neuron depletion induced by neurotoxins in PD animal models and therefore is neuroprotective. Estrogen may also decrease the efficacy of other neuroprotective substances such as caffeine in females but not males. Sex chromosomes can exert effects independent of sex steroid hormones on the development and maintenance of the dopamine system. As a result of hormone, chromosome and other unknown effects, there are sexual dimorphisms in the basal ganglia, and at the molecular levels in dopaminergic neurons that may lead to distinct mechanisms of pathogenesis in males and females. In this review, we summarize the evidence that estrogen and selective estrogen receptor modulators are neuroprotective in PD and discuss potential mechanisms of action. We also briefly review how sex differences in basal ganglia function and dopaminergic pathways may impact HD, chorea, and tics/Tourette's syndrome. Further understanding of these sex differences may lead to novel therapeutic strategies for prevention and treatment of these diseases.
authors.affiliation: Parkinson's Disease and Movement Disorders Center, 330 S. 9th St, 2nd Floor, Philadelphia, PA 19107, USA. Electronic address: kara.smith@uphs.upenn.edu.
authors.forename: Kara M
authors.initials: KM
authors.lastname: Smith
authors.affiliation: Parkinson's Disease and Movement Disorders Center, 330 S. 9th St, 2nd Floor, Philadelphia, PA 19107, USA.
authors.forename: Nabila
authors.initials: N
authors.lastname: Dahodwala
mesh_terms: D000728:Androgens / Q000494:pharmacology; D000818:Animals; D002110:Caffeine / Q000494:pharmacology; D020150:Chorea Gravidarum / Q000453:epidemiology / Q000503:physiopathology; D004298:Dopamine / Q000502:physiology; D004967:Estrogens / Q000494:pharmacology / Q000502:physiology; D005260:Female; D006801:Humans; D006816:Huntington Disease / Q000453:epidemiology / Q000503:physiopathology; D008297:Male; D009069:Movement Disorders / Q000453:epidemiology* / Q000503:physiopathology*; D018696:Neuroprotective Agents / Q000494:pharmacology; D010300:Parkinson Disease / Q000453:epidemiology* / Q000503:physiopathology*; D011374:Progesterone / Q000494:pharmacology; D012727:Sex Characteristics; D015398:Signal Transduction / Q000187:drug effects; D020323:Tics / Q000453:epidemiology / Q000503:physiopathology; D005879:Tourette Syndrome / Q000453:epidemiology / Q000503:physiopathology
chemical_list: D000728:Androgens; D004967:Estrogens; D018696:Neuroprotective Agents; D002110:Caffeine; D011374:Progesterone; D004298:Dopamine
keywords: Chorea; Estrogen; Huntington's disease; Neuroprotection; Parkinson's disease; Sex chromosome; Sex differences; Testosterone; Tics; Tourette's syndrome